Several mergers and acquisitions are afoot in Medicare Advantage.
Here are nine updates on the program Becker's has reported since Dec. 19.
- Medicare Advantage beneficiaries are more likely to be prescribed biosimilar drugs than their counterparts in traditional Medicare, a study published in JAMA Health Forum found.
- A Medicare Advantage plan jointly owned by Essence Healthcare and Stanford (Calif.) Health Care exited the California market Jan. 1.
- Cigna is nearing a deal to sell its Medicare Advantage business to Health Care Service Corp., according to a Wall Street Journal report. People familiar with the deal told the Journal Cigna is in exclusive talks with HCSC to sell the Medicare Advantage business for between $3 and $4 billion.
- Bright Health closed the sale of its California Medicare Advantage business to Molina Healthcare. The deal will significantly expand Molina's Medicare Advantage business, adding 109,000 members.
- Devoted Health, a startup Medicare Advantage plan, raised $175 million in series E funding. The company has over 140,000 members and expanded to serve 13 states in 2023.
- In July, Reps. Michael Burgess, MD, and Vicente Gonzalez, both of Texas, introduced gold card legislation that would exempt qualifying providers from prior authorization requirements for Medicare Advantage plans. Dr. Burgess, a retired OB-GYN, recently spoke to the American Hospital Association about why he is pursuing the bill.
- UnitedHealthcare has at least 75% of the Medicare Advantage market in three major cities, according to the American Medical Association. Here are the cities where UnitedHealthcare had its largest market share in 2022.
- A pair of senators asked CMS to require Medicare Advantage plans to cover stays in long-term care facilities at the same rate as traditional Medicare.
- The Justice Department wants Humana's lawsuit challenging a CMS rule that would implement stricter auditing standards on Medicare Advantage plans moved to a different court, then thrown out. In a Dec. 18 court filing, attorneys argued Humana and its Texas subsidiary, based in Dallas, have no basis to file in the Fort Worth District.